| Sep 4 |
3 Stocks Estimated To Be Up To 45% Below Intrinsic Value
|
| Sep 4 |
Exploring High Growth Tech Stocks for September 2024
|
| Aug 29 |
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
|
| Aug 28 |
argenx to Present at Upcoming Investor Conferences
|
| Aug 12 |
Biotech stocks: Which drugmakers are worth a buy?
|
| Aug 10 |
Piper lists eight defensive biotechs to face market volatility
|
| Aug 6 |
Argenx raised to Overweight at Barclays on long-term prospects
|
| Jul 31 |
Three Stocks That Could Be Trading Below Fair Value In July 2024
|
| Jul 30 |
Argenx (ARGX) Upgraded to Buy: Here's What You Should Know
|
| Jul 29 |
Northrop Grumman To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
|
